Aspen Pharmacare CEO Stephen Saad. Picture: SUPPLIED
Loading ...
Aspen has posted a 10% rise in interim revenue, supported by growth in commercial pharmaceuticals, as well as manufacturing. The pharmaceutical group’s bottom line however took a knock, as headline earnings per share dropped 6%. Business Day TV spoke to CEO Stephen Saad for more detail.
Loading ...
Loading ...
View Comments